4 August 2022 in Arthritis & Rheumatology
Objectives: Psoriatic arthritis (PsA) has a strong genetic component, and the identification of genetic risk factors could help identify the ~30% of psoriasis patients at high risk of developing PsA. Our objectives were to identify genetic risk factors and pathways that differentiate PsA from cutaneous‐only psoriasis (PsC) and to evaluate the performance of PsA risk prediction models.Methods: Genome‐wide meta‐analyses were conducted separately for 5,065 patients with PsA and 21,286 healthy controls and separately for 4,340 patients with PsA and 6,431 patients with PsC. The heritability of PsA was calculated as a single‐nucleotide polymorphism (SNP)–based heritability estimate (h2SNP) and biologic pathways that differentiate PsA from PsC were identified using Priority Index software. The generalizability of previously published PsA risk prediction pipelines was explored, and a risk prediction model was developed with external validation.Results: We identified a novel genome‐wide significant susceptibility locus for the development of PsA on chromosome 22q11 (rs5754467; P = 1.61 × 10−9), and key pathways that differentiate PsA from PsC, including NF‐κB signaling (adjusted P = 1.4 × 10−45) and Wnt signaling (adjusted P = 9.5 × 10−58). The heritability of PsA in this cohort was found to be moderate (h2SNP = 0.63), which was similar to the heritability of PsC (h2SNP = 0.61). We observed modest performance of published classification pipelines (maximum area under the curve 0.61), with similar performance of a risk model derived using the current data.Conclusion: Key biologic pathways associated with the development of PsA were identified, but the investigation of risk classification revealed modest utility in the available data sets, possibly because many of the PsC patients included in the present study were receiving treatments that are also effective in PsA. Future predictive models of PsA should be tested in PsC patients recruited from primary care.
17 January 2024 in Arthritis & Rheumatology
Objective: There is growing evidence that genetic data are of benefit in the rheumatology outpatient setting by aiding early diagnosis. A genetic probability tool (G‐PROB) has been developed to aid diagnosis has not yet been tested in a real‐world setting. Our aim was to assess whether G‐PROB could aid diagnosis in the rheumatology outpatient setting using data from the Norfolk Arthritis Register (NOAR), a prospective observational cohort of patients presenting with early inflammatory arthritis.Methods: Genotypes and clinician diagnoses were obtained from patients from NOAR. Six G‐probabilities (0%–100%) were created for each patient based on known disease‐associated odds ratios of published genetic risk variants, each corresponding to one disease of rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, spondyloarthropathy, gout, or “other diseases.” Performance of the G‐probabilities compared with clinician diagnosis was assessed.Results: We tested G‐PROB on 1,047 patients. Calibration of G‐probabilities with clinician diagnosis was high, with regression coefficients of 1.047, where 1.00 is ideal. G‐probabilities discriminated clinician diagnosis with pooled areas under the curve (95% confidence interval) of 0.85 (0.84–0.86). G‐probabilities 2 unlikely diseases for 94% of patients and >3 for 53.7% of patients. G‐probabilities >50% corresponded to a positive predictive value of 70.4%. In 55.7% of patients, the disease with the highest G‐probability corresponded to clinician diagnosis.Conclusion: G‐PROB converts complex genetic information into meaningful and interpretable conditional probabilities, which may be especially helpful at eliminating unlikely diagnoses in the rheumatology outpatient setting. image
1 February 2000 in The Quarterly Journal of Experimental Psychology Section A
Three experiments investigated cross-form transfer in the invariance learning paradigm introduced by McGeorge and Burton (1990). The results suggest that the transfer observed by McGeorge and Burton depended on subjects’ ability to use a response strategy discovered by Wright and Burton (1995). When that strategy was denied to subjects (Experiments 1 and 2), no cross-form transfer was observed; when the strategy was made available (Experiment 3), cross-form transfer re-emerged. These results suggest that this form of learning, like many other forms of implicit learning and memory, is hyperspecific.
14 June 2025 in Rheumatology International
To map from the health assessment questionnaire disability index (HAQ) to the pain visual analogue scale (VAS) for people with rheumatoid arthritis. The estimation sample comprised adults with rheumatoid arthritis and inadequate response to tumour necrosis factor-α inhibitors in a multicentre phase 4 randomised controlled trial. Beta mixture models were estimated with combinations of HAQ and its square, age and sex as independent variables. Bayesian Information Criteria informed the number of components. Model performance (root mean squared error; mean absolute error; pseudo-R2) was estimated by k-fold cross validation. Graphs illustrated mean observed and predicted pain VAS, and cumulative distribution of observed and simulated pain VAS values. For face validity, a probabilistic analysis simulated 5000 pain VAS values at four HAQ scores. For external validation, the performance of the preferred specification was assessed using the Rheumatoid Arthritis Medication Study cohort. There were 1055 observations from 158 participants in the estimation sample (mean age: 55.8; 81% female; mean HAQ: 1.72). The preferred specification was a two-component beta mixture model (probability variables: HAQ, age, sex; main regression variable: HAQ). Visual plots illustrated good fit across the HAQ distribution, and a similar cumulative distribution of observed and predicted pain VAS values. Probabilistic analysis demonstrated that the preferred specification handled uncertainty appropriately. External validation demonstrated that the preferred specification performed well in an independent dataset. Beta mixture models provide accurate non-linear estimates of pain VAS from HAQ scores to support evidence synthesis and resource allocation decision-making for people with rheumatoid arthritis.
1 January 2026 in RMD Open
Objectives: To develop response criteria for rheumatoid arthritis (RA) using the two-component Disease Activity Score in 28 joints (2C-DAS28). Methods: Data were available for three stages of RA treatment progression, determined by the disease-modifying antirheumatic drug prescribed: early (on methotrexate; n=1051), established (on tumour necrosis factor inhibitors; n=989) and late RA (on second-line or later therapy; n=301). Inflammation response was defined as achieving remission or a clinically meaningful reduction in disease activity after 3 months of treatment. Corresponding 2C-DAS28 thresholds were determined using receiver operating characteristic analysis and Youden’s J, based on Boolean V.2.0 remission and clinical disease activity index response. The correlation of the proposed criteria with synovial thickness (ST) and power Doppler (PD) was assessed in an independent cohort (n=161) and compared with conventional response criteria. Finally, 6-month disease activity was compared between 3-month 2C-DAS28 responders and non-responders. Results: Thresholds to define inflammation response were 2C-DAS281.7. In the validation cohort, 3-month 2C-DAS28 response was significantly correlated with lower ST (r=−0.25 (95% CI −0.47 to −0.04), p=0.037) and PD scores (r=−0.28 (95% CI −0.52 to −0.04), p=0.042). By contrast, conventional response criteria showed no significant correlation with synovitis scores. In the discovery cohorts, 3-month 2C-DAS28 responders retained lower disease activity at 6 months than non-responders. Conclusion: 2C-DAS28 response correlates significantly with ultrasound-detected synovitis and is associated with improved clinical outcomes. This may support identification of biomarkers of treatment efficacy and clinical stratification, to identify patients with ongoing inflammation and those in whom disease activity is driven by non-inflammatory features.
22 December 2025 in Rheumatology Advances in Practice
Objectives: To investigate the clinical use of steroids in established RA. Methods: A cohort of RA patients commencing treatment with biologic or targeted synthetic (b/ts) DMARDs was followed prospectively, with clinical data recorded pre-baseline and at the 3, 6 and 12-month follow-up. Patients were included in this analysis if they had completed the first year of follow-up and had data on steroid use available for at least one follow-up. The proportions of patients receiving steroids at different timepoints were compared and further differentiated between continued (receiving steroids at two consecutive timepoints) and newly started treatment. Lastly, mixed linear effect models were used to assess the relationship between clinical factors and steroid use. Results: The cohort (N = 1846) had a median disease duration of 7 years and, across each timepoint, ≈30% of patients received steroids, up to two-thirds of which continued treatment from a preceding follow-up. At 12 months, the proportion of patients continuing treatment decreased, but more patients started steroid treatment (P < 0.001). Linear mixed effects modelling further showed that steroid use was more common in patients who had required pre-baseline steroids [odds ratio (OR) 1.44 (95% CI 1.38, 1.49)] and in those on later-stage treatments [OR 1.15 (95% CI 1.08, 1.23)]. Conclusion: Despite the introduction of b/tsDMARDs, steroid use in this cohort continued over the first year of follow-up, particularly in patients with more severe RA. Together with previous data, this further highlights the need for future research and trials to better understand the right course of steroid administration to maximize efficacy and limit adverse side effects.